.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has picked Eli Lilly (NYSE: LLY) as its leading biopharma choice for 2025 and also rated another 9 names in the area as over weight. The assets financial institution said in a keep in mind that it continues to feel “diabesity is actually readied to become.